Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford. A yeast genetics research group led by Professor Tim Humphrey in Oxford discovered an Achilles heel of certain cancer cells – mutations in a gene called SETD2. Prof Humphrey and his team showed that cancer cells with a mutated SETD2 gene were killed by an experimental drug being developed by Astra Zeneca called AZD1775 which inhibits a protein called WEE1.
Congratultions to everyone in Old Road Campus Research Building’s Green Impact team, which includes various members of staff from Departments within the Building including Oncology, and also to everyone in the building who has helped achieve a silver award for environmental sustainability projects.
The announcement was made at a recent ceremony, held at the Sheldonian Theatre, and the award will be displayed in the reception.
New research led by Queen’s University Belfast in collaboration with the University of Oxford, has discovered how a genomic approach to understanding colorectal cancer could improve the prognosis and quality of life for patients.
FOXFIRE Combined Analysis indicates no benefit in overall survival from adding selective internal radiotherapy [SIRT] to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer.
Secondary analyses confirm improved control of liver metastases with liver-directed SIRT and show clinical benefit in patients with liver metastases originating from difficult-to-treat right-sided colon cancer.
Five members of Professor Len Seymour's laboratory (Arthur Dyer, Sally Frost, Sophie Owen, Tzveta Pokrovska and Ellie Scott) are limbering up to walk 100km non-stop in 24 hours over the August bank holiday to raise money for Cancer Research UK, Martlet's Hospice and the Red Cross.
If you have any spare money and would like to support them please visit the Just Giving page – all donations are greatly appreciated.
In advance of any donations received the “Angels” thank you for your support.
Joshua Bugajski (Stroke 4), an MSc Oncology student in Katherine Vallis’ group was part of Oxford’s winning team on Sunday, 2 April when they cruised to victory in the 2017 Cancer Research UK boat race against Cambridge.
Oxford won the toss and chose the Surrey station. The crew took an early lead over Cambridge and this was Oxford’s 80th win in the event’s history – just 2 behind their rivals.
(photo credited to Getty Images)
It was announced in August 2016 that Professor Valentine Macaulay was awarded the 2016 Oxford Harrington Scholarship. Professor Macaulay’s work focuses on understanding growth factor receptor function, and the award was given to support novel approaches to disrupt receptor function as therapy for cancer. "I am honoured to be selected as the 2016 Oxford Harrington Scholar" said Professor Macaulay, "and I will do my utmost to exploit the opportunities provided by this award.".
The development of new treatments for pancreatic cancer is set to be transformed by a network of pancreatic clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK announced today.
The investment will support the PRECISION Panc project which aims to develop personalised treatments for pancreatic cancer patients, improving the options and outcomes for a disease where survival rates have remained stubbornly low.
The inaugural Oxfordshire Apprenticeship Awards recognised the best talent in the county at a presentation evening on Wednesday, 8 March at the Marlborough Enterprise Centre in Woodstock during the 10th National Apprenticeship Week.
Using funding from CRUK and Psioxus Therapeutics, a team of researchers from the University of Oxford led by Professor Len Seymour, have recently published a paper in Molecular Therapy Oncolytics.